AndroGel (Testosterone Topical) and Erythrocytosis: When to Call the Doctor

AndroGel is the brand name for testosterone gel, a topical (transdermal) formulation of testosterone, the primary male androgen. It is FDA-approved for men with confirmed hypogonadism, meaning low testosterone with an identified medical cause, and comes in 1% and 1.62% strengths applied daily to the skin. This article covers one specific, well-documented laboratory side effect of testosterone therapy in general and AndroGel in particular: erythrocytosis, an abnormal rise in red blood cell mass.

Erythrocytosis, a hematocrit rise above roughly 50% to 52%, is the most frequently reported laboratory abnormality on testosterone replacement therapy, including AndroGel. Guideline bodies generally treat a hematocrit above 54% as the point at which testosterone therapy should be paused and the patient evaluated for contributing causes such as sleep apnea before resuming at a lower dose. Topical gels are widely described in the literature as carrying a lower erythrocytosis burden than intramuscular injections because they avoid the sharp, supraphysiologic testosterone peaks injections produce, but exact comparative incidence numbers vary across studies and should not be treated as fixed statistics without checking the primary trial or registry report behind them.

What erythrocytosis means, and what it does not

Erythrocytosis is a sustained rise in red blood cell concentration, tracked clinically through hematocrit (the percentage of blood volume occupied by red cells) or hemoglobin. It is a secondary, dose-related effect of testosterone, not a disease in its own right.

It is worth separating this clearly from polycythemia vera, a bone marrow disorder driven by a JAK2 gene mutation. Testosterone-induced erythrocytosis is reactive: it results from testosterone's effects on iron handling and erythropoietin signaling, and it generally reverses when the testosterone dose is lowered or stopped. The two conditions are managed very differently, and a persistently high hematocrit that does not respond to dose adjustment warrants hematology evaluation to rule out a primary blood disorder.

Not every man who crosses a hematocrit of 50% is at meaningful risk. The rate of rise, baseline cardiovascular risk, hydration at the time of the blood draw, and altitude of residence all affect how a given number should be interpreted. A man living at elevation, for example, may have a physiologically higher baseline hematocrit before treatment even starts.

Why testosterone raises red blood cell counts

Two mechanisms are generally described in the endocrinology literature. First, testosterone suppresses hepcidin, the liver hormone that limits how much iron the body absorbs and recycles; lower hepcidin frees up more iron for red blood cell production. Second, testosterone appears to stimulate erythropoietin (EPO) production from the kidney independent of any true drop in tissue oxygen.

Both mechanisms are dose-related, which is consistent with the clinical observation that higher testosterone doses and higher peak serum levels produce a larger hematocrit response. The magnitude of hepcidin suppression and the size of the resulting hemoglobin increase reported in specific studies vary, and any precise figure quoted for either effect should be checked against the original trial report before being repeated as an established number.

AndroGel's pharmacokinetic profile matters here. Daily topical application produces relatively steady serum testosterone levels through the day, without the sharp peak that intramuscular injections produce in the days after a dose. Because the erythropoietic drive is thought to track peak testosterone exposure, this steadier profile is one plausible explanation for gels generally showing a lower reported erythrocytosis rate than injections in observational data, though this is a comparison across different study populations and designs rather than a head-to-head randomized trial.

A decision framework: what your hematocrit number should trigger

The number on a lab report only matters in the context of trend, symptoms, and individual risk. The following framework reflects the general threshold used by major U.S. endocrine and urology guideline bodies, adapted for practical use. It is not a substitute for your prescriber's judgment about your specific case.

Two exceptions worth flagging to your clinician rather than assuming apply automatically: a hematocrit that rises quickly over a few weeks deserves more urgency than a slow drift over a year, and a man with known chronic lung disease, untreated sleep apnea, or a history of blood clots should generally be managed more conservatively at any given hematocrit than someone without those risk factors.

When to call your doctor versus when to go to the emergency department

Some symptoms warrant a call the same day. Others warrant urgent, in-person evaluation regardless of what your last hematocrit was.

Call your prescriber within 24 hours if you notice:

• A persistent headache that does not respond to over-the-counter medication, especially one that worsens lying down
• New or worsening facial flushing or ruddy skin color that persists outside of exercise
• Home blood pressure readings that are meaningfully higher than your usual baseline
• Fatigue or mental fogginess that gets worse rather than better on testosterone, which can be a sign of high blood viscosity rather than low testosterone

Go to the emergency department for:

• Sudden, severe headache with vision changes
• Chest pain, pressure, or tightness, particularly with exertion
• One-sided leg swelling with warmth or pain, which can signal a blood clot
• Shortness of breath at rest or with minimal activity
• Sudden weakness, numbness, or trouble speaking on one side of the body

There is no single hematocrit number that by itself defines an emergency. A patient with a hematocrit of 53% and new chest pain needs urgent evaluation just as much as one with a hematocrit of 58%. Symptoms and their tempo matter more than the isolated lab value.

The FDA's 2015 safety communication on testosterone products added warnings about venous blood clot risk across the testosterone class, which is part of why elevated hematocrit is taken seriously as a modifiable risk factor rather than an incidental lab finding.

A large randomized cardiovascular safety trial of testosterone therapy (the TRAVERSE trial, published in the New England Journal of Medicine in 2023) reported more erythrocytosis in the testosterone arm than placebo, while its primary cardiovascular safety endpoint did not show a statistically significant difference between groups. Readers and clinicians who want the exact incidence figures and timing from that trial should consult the published trial report directly rather than relying on a secondhand number, since precise percentages circulating online for this trial are not consistently sourced correctly.

How clinicians typically manage it

Management usually proceeds in steps rather than jumping straight to the most invasive option.

Dose reduction is generally tried first. Because AndroGel is dosed by metered pump actuations or single-use packets, a prescriber can lower the daily dose (for example, fewer pump actuations of the 1.62% formulation, or a smaller packet size of the 1% formulation) and recheck hematocrit in several weeks.

Therapeutic phlebotomy, removing a unit of whole blood, is used as a temporizing measure when hematocrit needs to come down more quickly, such as before an elective procedure or when dose reduction alone has not been sufficient. It is not intended as a long-term substitute for an appropriate testosterone dose, since repeated phlebotomy without addressing the underlying dose can lead to iron deficiency and does not treat the cause.

Evaluating for a contributing cause, particularly obstructive sleep apnea, is recommended whenever erythrocytosis develops or persists despite reasonable dosing, because untreated sleep apnea independently raises red blood cell production and can push a borderline testosterone-related rise over the action threshold.

Switching formulations is sometimes discussed. Injectable testosterone generally carries a higher reported erythrocytosis rate than topical gel in observational data, so switching from injections to a gel is a more plausible strategy than the reverse. If you are already on AndroGel and developing erythrocytosis, switching to an injectable is unlikely to help and could make hematocrit management harder.

How long it takes to develop and to resolve

Red blood cells live for roughly 120 days, and that lifespan shapes both the onset and the resolution of testosterone-related erythrocytosis. In general, hematocrit begins to rise within the first few weeks of starting therapy and tends to reach a new steady state within the first several months, which is why most monitoring schedules concentrate testing in that early window. A rise that first appears after a year or more of stable dosing is less likely to be a simple dose effect and deserves evaluation for a new contributing cause, such as newly developed sleep apnea or another source of chronic hypoxia.

After stopping testosterone, hematocrit generally declines over one to three months as red cells are not replaced at the same rate; phlebotomy can shorten this timeline when a faster reduction is medically needed.

Who is more likely to develop it

Several factors are consistently associated with a higher risk of testosterone-related erythrocytosis in the literature, though the exact size of each effect varies by study:

• Older age. Older men on testosterone therapy in published trials have shown measurable hemoglobin increases and a meaningful minority crossing guideline thresholds during monitored follow-up.
• Untreated obstructive sleep apnea, which independently raises red blood cell production through intermittent low oxygen and adds to any testosterone-related effect.
• Higher altitude residence, which raises baseline hematocrit before treatment starts, narrowing the margin before reaching an action threshold.
• Higher testosterone doses or trough levels pushed toward the upper end or above the normal range, since the erythropoietic effect tracks dose.
• Obesity and coexisting metabolic conditions, partly because of a higher likelihood of undiagnosed sleep-disordered breathing.

Monitoring while on AndroGel

A reasonable monitoring cadence, consistent with major U.S. guideline recommendations, includes a baseline complete blood count and testosterone level before starting, a recheck around three to six months into therapy (the period when early erythrocytosis is most likely to appear), a full panel at twelve months, and annual monitoring after that. If hematocrit is trending upward on consecutive draws, more frequent checks are reasonable even outside this schedule.

Hydration at the time of the blood draw matters: dehydration can concentrate the blood and inflate the hematocrit reading without reflecting a true change in red cell mass. If a result looks unexpectedly high, it is reasonable to confirm hydration status and repeat the test before changing treatment.

What is established, what is plausible, and what is not established

Established: Testosterone therapy, including topical gel, raises hematocrit in a dose-related way for a meaningful proportion of patients. Major U.S. guideline bodies use a hematocrit above 54% as an action threshold to pause therapy and evaluate for contributing causes. Elevated hematocrit is a recognized modifiable factor in venous blood clot risk, which is why the FDA's class-wide testosterone label carries a blood clot warning.

Plausible but not fully settled: That topical gels carry a meaningfully lower erythrocytosis risk than injections in a way that would change day-to-day management decisions for an individual patient, beyond the general pharmacokinetic rationale. That switching formulations for erythrocytosis management (rather than dose reduction) is broadly superior. Precise numeric comparisons between formulations circulating in secondary sources are not consistent enough to be quoted as fixed figures without checking the original study.

Not established: That testosterone-induced erythrocytosis, by itself and without other risk factors, causes a clearly elevated risk of major cardiovascular events; the largest recent cardiovascular safety trial in this area did not find a statistically significant increase in its primary composite cardiovascular endpoint despite finding more erythrocytosis in the testosterone group. This should not be read as reassurance to ignore a rising hematocrit, since the trial population, dosing, and monitoring protocol may not match an individual patient's situation.

Common questions

References

A note for the reviewing clinician: several precise incidence figures, effect sizes, and named quotations that appeared in the prior draft of this article (including specific percentages attributed to AndroGel's label, comparative injection-versus-gel erythrocytosis rates, TRAVERSE trial sub-results, and quotations attributed to named researchers) could not be verified against a confirmed primary source in this pass and have been removed, generalized, or flagged above. Please confirm any numeric claim before it is republished, and add specific citations only after checking that the source actually supports the exact figure and population described.